<SEC-DOCUMENT>0001140361-26-023475.txt : 20260601
<SEC-HEADER>0001140361-26-023475.hdr.sgml : 20260601
<ACCEPTANCE-DATETIME>20260601111252
ACCESSION NUMBER:		0001140361-26-023475
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260601
DATE AS OF CHANGE:		20260601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				043145961
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		261048142

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ny20075156x1_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 540pt;"><a name="ny20075156x1_defa14a_100-regcov_pg1"><!--Anchor--></a><div class="BRDSX_block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 540pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><font style="font-size: 12pt;">Washington, D.C. 20549</font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SCHEDULE 14A INFORMATION </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Proxy Statement Pursuant to Section&#160;14(a) of the <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities Exchange Act of 1934<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Amendment No. ___) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 12pt; width: 540pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 176pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 352pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 176pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filed by the Registrant </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 352pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612; </div></td></tr><tr><td style="width: 176pt; padding-top: 1.01pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filed by a Party other than the Registrant </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 352pt; padding-top: 1.34pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 176pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 352pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Check the appropriate box: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 1pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 522pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 6pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font><font style="font-size: 10pt;"> </font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 522pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preliminary Proxy Statement </div></td></tr><tr><td style="width: 6pt; padding-top: 1.34pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font><font style="font-size: 10pt;"> </font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 522pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) </div></td></tr><tr><td style="width: 6pt; padding-top: 1.34pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font><font style="font-size: 10pt;"> </font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 522pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definitive Proxy Statement </div></td></tr><tr><td style="width: 6pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612; </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 522pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Definitive Additional Materials </div></td></tr><tr><td style="width: 6pt; padding-top: 1.34pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font><font style="font-size: 10pt;"> </font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 522pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Soliciting Material Pursuant to Section 240.14a-12</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 522pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Anika Therapeutics, Inc. <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">(Name of Registrant as Specified in its Charter) </font><br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Not applicable. <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div><div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Payment of Filing Fee (Check all boxes that apply): </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 1pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 522pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 6pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#x2612; </div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 522pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">No fee required. </div></td></tr><tr><td style="width: 6pt; padding-top: 1.34pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font><font style="font-size: 10pt;"> </font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 522pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fee paid previously with preliminary materials. </div></td></tr><tr><td style="width: 6pt; padding-top: 1.34pt; text-align: left; vertical-align: top;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<font style="font-size: 10pt; font-family: Arial, Helvetica, sans-serif;">&#x2610;</font><font style="font-size: 10pt;"> </font></div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 522pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 6pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 522pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div><div class="BRDSX_block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20075156x1_defa14a_101-notice_pg1"><!--Anchor--></a><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ANIKA THERAPEUTICS, INC. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">SUPPLEMENT TO PROXY STATEMENT FOR <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE ANNUAL MEETING OF STOCKHOLDERS <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">To Be Held On June&#160;18, 2026 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; text-align: right;">June 1, 2026 </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On April&#160;28, 2026, Anika Therapeutics, Inc. (the &#8220;<u>Company</u>&#8221;) filed a definitive proxy statement (the &#8220;<u>Proxy </u><u>Statement</u>&#8221;) for its 2026 Annual Meeting of Stockholders (the &#8220;<u>Annual Meeting</u>&#8221;), to be held on Thursday, June&#160;18, 2026, at 8:30 a.m. Eastern time. You may participate in the Annual Meeting, including casting votes and asking questions, by accessing a live webcast at <font style="font-style: italic;">virtualshareholdermeeting.com/ANIK2026. </font>This supplement (this &#8220;<u>Supplement</u>&#8221;) to the Proxy Statement amends and supplements the Proxy Statement as filed and should be read in conjunction with the Proxy Statement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Proposal 4 (the &#8220;<u>Plan Proposal</u>&#8221;) of the Proxy Statement requests that the Company&#8217;s stockholders approve the sixth amendment and restatement of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the &#8220;<u>Seventh </u><u>Amended Plan</u>&#8221;), which Seventh Amended Plan was approved by the Company&#8217;s Board of Directors on April&#160;26, 2026. After making the Proxy Statement available to stockholders, the Company was informed by Institutional Shareholder Services (&#8220;<u>ISS</u>&#8221;) that the Seventh Amended Plan received an unfavorable recommendation, in part because ISS has estimated that the Seventh Amended Plan is estimated to be excessively dilutive. In calculating dilution for the Seventh Amended Plan, ISS based its estimate in part on stock options outstanding as part of the calculation of shares subject to the Sixth Amended Plan as of April&#160;21, 2026 as set forth in the Proxy Statement on page 89, which, total Stock Options Outstanding amount of 2,231,740 shares includes 476,221 shares underlying stock appreciation rights (&#8220;<u>SARs</u>&#8221;) that the Company can settle in cash or stock at the Company&#8217;s election. In order to clarify this disclosure, the Company is amending and restating the table included on page 89 of the Proxy Statement to exclude the shares underlying these SARs from the total amount. Other than as set forth below, the Company is not changing or supplementing any of the other information in the Proxy Statement. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Shares Subject to the Plan </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes information regarding awards outstanding and shares of our common stock remaining available for grant under the Sixth Amended Plan as of April&#160;21, 2026: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 417pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 45pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 417pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock Options Outstanding<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> <font style="padding-left: 4.94pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">2,231,740</font> </div></td></tr><tr><td style="width: 417pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted Average Exercise Price of Stock Options Outstanding <font style="padding-left: 2.22pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 17.5pt;">&#8203;27.15 </font></div></td></tr><tr><td style="width: 417pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted Average Remaining Term of Stock Options Outstanding <font style="padding-left: 2.53pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 27.5pt;">6.19 </font></div></td></tr><tr><td style="width: 417pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Full Value Awards Outstanding (RSAs, RSUs and PSUs)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup> <font style="padding-left: 1.07pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">342,713 </font></div></td></tr><tr><td style="width: 417pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares Available for Grant under the Sixth Amended Plan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup> <font style="padding-left: 2.38pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">318,707</font> </div></td></tr><tr><td style="width: 417pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares Available for Grant under the 2021 Inducement Plan <font style="padding-left: 3.36pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">67,600</font></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 417pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 45pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Stock Options Outstanding includes 476,221 shares underlying Stock Appreciation Rights (SARs) granted in 2026 which may be settled in cash or stock at the Company&#8217;s election. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">The Phantom RSUs and Phantom PRSUs granted in 2024, 2025 and 2026 have been recorded by the Company as a liability due to the current expectation that the Company will settle some or all of the Phantom RSU and Phantom PRSU awards in cash due to a potential shortage of shares in the 2017 Plan at the time of vesting, and are not included. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Shares Available for Grant under the Sixth Amended Plan assumes that all 476,221 shares underlying SARs granted in 2026 will be settled in shares. The Seventh Amended Plan will continue to employ a &#8220;fungible&#8221; plan design that assigns a higher cost to &#8220;full-value&#8221; awards (all awards other than stock options and stock appreciation rights) by reducing the share pool on a greater than one-for-one basis when full-value shares are granted. Consistent with the terms of the Original Plan and each of the First, Second, Third, Fourth, Fifth, and Sixth Amended Plans, we have maintained a fungible rate of 2.0 common shares per full-value award in the Seventh Amended Plan. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Board Recommendation </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE &#8220;FOR&#8221; THE AMENDMENT OF THE SIXTH AMENDED PLAN IN THE FORM OF THE SEVENTH AMENDED PLAN ATTACHED AS&#160;<font style="font-style: italic;">APPENDIX A</font> TO THIS PROXY STATEMENT.<font style="font-weight: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any vote &#8220;FOR&#8221; or &#8220;AGAINST&#8221; Proposal 4 for approval of the Amendment of the Sixth Amended Plan in the Form&#160;of the Seventh Amended Plan attached as Appendix A to the Proxy Statement using the proxy materials previously furnished by the Company (or a beneficial owner&#8217;s broker, bank, or other nominee) will continue to be counted as a vote &#8220;FOR&#8221; or &#8220;AGAINST&#8221; such proposal. </div></div></div></div>
<!--End Page 2-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20075156x1_defa14a_101-notice_pg2"><!--Anchor--></a><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If you are a stockholder of record, and you have already voted and would like to change your vote, you may change or revoke your proxy at any time before it is exercised by: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Written notification to the Corporate Secretary of the Company at Office of the Secretary, Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Voting via the internet or telephone at a later time; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Submitting a validly executed proxy card with a later date; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Voting via the internet at the Annual Meeting. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If you are a beneficial owner of shares held in street name, you should contact your bank, broker, or other nominee for instructions as to whether, and how, you can change or revoke your proxy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">All costs of solicitation of proxies will be borne by us. In addition to solicitation by mail, our directors, officers, and employees, without additional remuneration, may solicit proxies in person or by telephone, e-mail, and facsimile. We will reimburse banks, brokerage firms, and other custodians, nominees, trustees, and fiduciaries for reasonable out-of-pocket expenses incurred by them in sending proxy materials to and soliciting proxies from beneficial holders of our shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This Supplement to the Proxy Statement is being released on or about June 1, 2026, and should be read in conjunction with the Proxy Statement. The information contained in this Supplement to the Proxy Statement modifies or supersedes any inconsistent information contained in the Proxy Statement. The information provided above may be deemed &#8220;additional soliciting materials&#8221; within the meaning of the Securities Exchange Act of 1934, as amended. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Important Information </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the solicitation of proxies, the Company filed the Proxy Statement on April&#160;28, 2026 with the U.S. Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;). Stockholders can access the Proxy Statement and other proxy materials and vote at&#160;<font style="font-style: italic;">www.proxyvote.com</font>. THE COMPANY&#8217;S STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT SOLICITATION MATERIALS FILED BY THE COMPANY WITH THE SEC BEFORE MAKING ANY VOTING OR INVESTMENT DECISION BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION. In addition, the Company files annual, quarterly and current reports with the SEC. These reports can be obtained free of charge on our investor relations website at&#160;<font style="font-style: italic;">https://ir.anika.com/sec-filings</font> and the SEC&#8217;s<font style="font-style: italic;"> </font>website at <font style="font-style: italic;">www.sec.gov</font>. The Proxy Statement, copies of other solicitation materials and these other reports the Company files with the SEC can be obtained at no charge by writing to our Secretary at Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, MA 01730. </div></div></div></div>
<!--End Page 3-->
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
